24 Oct 2018 I The release and presentation materials are now available.
The 2019 Annual General Meeting is planned to be held on 26 March 2019 in Helsinki.
The results of the ARAMIS phase III trial of darolutamide in non-metastatic castration-resistant prostate cancer will be presented on 14 February 2019 at the Genitourinary Cancers Symposium (ASCO GU).
|1/9/2019||Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2019 AGM of Orion Corporation|
|10/30/2018||Composition of the Nomination Committee of Orion Corporation|
|10/24/2018||Orion Group Interim Report January-September 2018|
|10/24/2018||Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The primary endpoint was met|
|1/4/2019||Orion Corporation and Fifth Corner Inc join forces to research solutions for improving the quality of life of prostate cancer patients|
|12/4/2018||Orion acquires sales and distribution rights for certain European Countries for Parkinson's disease drug Stalevo|
|11/1/2018||Orion Research Foundation grants million euros for research in 2019|
|10/24/2018||Orion and Amgen to collaborate on the commercialisation of AMGEVITA® (biosimilar adalimumab) in Finland|
The Closing of the transaction took place on 30 April 2018.
Orion's key research projects include three ongoing Phase III trials, among others.
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.